ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Actinogen Medical Ltd (ASX:ACW) said its net loss after tax for the six months to December 2024 decreased by 29% to ...

COURTESY UH CANCER CENTER The Queen’s Health Systems and University of Hawaii Cancer Center will develop an oncology clinic at the UH John A. Burns School of Medicine in Kakaako. 1 /3 COURTESY UH ...

Objective This study aimed to investigate the incidence of overweight in patients with major depressive disorder (MDD) comorbid anxiety during the acute phase and to explore associated factors. Design ...

Researchers’ understanding of the pathogenesis of rheumatoid arthritis has grown considerably in recent years, laying the ...

If this CEO succeeds N-Power could save millions of dollars and lives in the fight against cancer. "The impact for cancer ...

The patch-delivered vaccine trial received $28.5m in funding from US authorities as a potential pandemic preparation.

Discover Zealand Pharma's Q4 2024 earning highlights, key obesity pipeline advancements, and future plans for petrelintide and dapiglutide.

The FARE Innovation Award Diagnostic Challenge is made possible through generous support from the Naddisy Foundation, the ...